File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/S0960-9776(07)70194-7
- WOS: WOS:000257274600164
- Find via
Supplementary
-
Citations:
- Web of Science: 0
- Appears in Collections:
Conference Paper: The experience of sentinel lymph node biopsy in Chinese breast cancer patients with prior neo-adjuvant chemotherapy
Title | The experience of sentinel lymph node biopsy in Chinese breast cancer patients with prior neo-adjuvant chemotherapy |
---|---|
Authors | |
Issue Date | 2007 |
Publisher | Churchill Livingstone. The Journal's web site is located at http://www.elsevier.com/locate/breast |
Citation | The 10th International Conference on Primary Therapy of Early Breast Cancer, St.Gallen, Switzerland, 14-17 March 2007. In The Breast, 2007, v. 16 suppl. 1, p. S51, abstract no. P134 How to Cite? |
Abstract | Objective: Sentinel lymph node biopsy (SLNB) is well accepted as part
of management of early breast cancer. As neo-adjuvant chemotherapy
(NACT) is increasingly used in management of locally advanced breast
cancer (LABC), breast conservative surgery has become a possibility even
for patients who initially present with large tumours. However reports on the
performance of sentinel lymph node biopsy (SLNB) following neo-adjuvant
chemotherapy (NACT) have been conflicting. In addition, limited number
of reports from Chinese breast cancer patients are available. This study
aims to evaluate the results of SLNB after neo-adjuvant chemotherapy in
Chinese breast cancer patients.
Methods: A retrospective study was performed for breast cancer patients
who had SLNB after prior neo-adjuvant chemotherapy. Adriamycin-based
or taxane-based chemotherapy was given as neo-adjuvant treatment. A
combination of radiopharmaceutical 99mTc-albumin colloid and Patent Blue
V dye was used to identify the sentinel lymph node (SLN). SLNB was
followed by standard axillary dissection in all patients.
Results: 365 patients received SLNB during the period of May 1999 to
April 2006. A total of 78 patients with neo-adjuvant chemotherapy followed
by SLNB were recruited. The SLN identification rate, false-negative rate
and accuracy rate were 83.3%, 24.2% and 73.1% respectively. SLNs were
identified in 11 (84.6%) of 13 patients with complete clinical response and
no false-negative SLN was found. SLNs were found in 54 (83.1%) of 65
patients with partial or no clinical response and false-negative rate was
25%. In the 7 patients with complete pathological response, 6 (85.7%)
had SLNs identified with no false-negative node. In the 71 patients with
partial or no pathological response, 59 (83.1%) had SLN identified with a
false-negative rate of 24.2%.
Conclusion: The failed localization and false-negative rates of SLNB
after neoadjuvant chemotherapy were unacceptably high in our cohort,
concurrent with various published studies. Inaccuracy increases in patients
with less than complete clinical or pathological tumor response. |
Persistent Identifier | http://hdl.handle.net/10722/182316 |
ISSN | 2023 Impact Factor: 5.7 2023 SCImago Journal Rankings: 1.688 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kwong, A | - |
dc.contributor.author | Suen, DTK | - |
dc.contributor.author | Cheung, TT | - |
dc.date.accessioned | 2013-04-22T02:06:10Z | - |
dc.date.available | 2013-04-22T02:06:10Z | - |
dc.date.issued | 2007 | - |
dc.identifier.citation | The 10th International Conference on Primary Therapy of Early Breast Cancer, St.Gallen, Switzerland, 14-17 March 2007. In The Breast, 2007, v. 16 suppl. 1, p. S51, abstract no. P134 | - |
dc.identifier.issn | 0960-9776 | - |
dc.identifier.uri | http://hdl.handle.net/10722/182316 | - |
dc.description.abstract | Objective: Sentinel lymph node biopsy (SLNB) is well accepted as part of management of early breast cancer. As neo-adjuvant chemotherapy (NACT) is increasingly used in management of locally advanced breast cancer (LABC), breast conservative surgery has become a possibility even for patients who initially present with large tumours. However reports on the performance of sentinel lymph node biopsy (SLNB) following neo-adjuvant chemotherapy (NACT) have been conflicting. In addition, limited number of reports from Chinese breast cancer patients are available. This study aims to evaluate the results of SLNB after neo-adjuvant chemotherapy in Chinese breast cancer patients. Methods: A retrospective study was performed for breast cancer patients who had SLNB after prior neo-adjuvant chemotherapy. Adriamycin-based or taxane-based chemotherapy was given as neo-adjuvant treatment. A combination of radiopharmaceutical 99mTc-albumin colloid and Patent Blue V dye was used to identify the sentinel lymph node (SLN). SLNB was followed by standard axillary dissection in all patients. Results: 365 patients received SLNB during the period of May 1999 to April 2006. A total of 78 patients with neo-adjuvant chemotherapy followed by SLNB were recruited. The SLN identification rate, false-negative rate and accuracy rate were 83.3%, 24.2% and 73.1% respectively. SLNs were identified in 11 (84.6%) of 13 patients with complete clinical response and no false-negative SLN was found. SLNs were found in 54 (83.1%) of 65 patients with partial or no clinical response and false-negative rate was 25%. In the 7 patients with complete pathological response, 6 (85.7%) had SLNs identified with no false-negative node. In the 71 patients with partial or no pathological response, 59 (83.1%) had SLN identified with a false-negative rate of 24.2%. Conclusion: The failed localization and false-negative rates of SLNB after neoadjuvant chemotherapy were unacceptably high in our cohort, concurrent with various published studies. Inaccuracy increases in patients with less than complete clinical or pathological tumor response. | - |
dc.language | eng | - |
dc.publisher | Churchill Livingstone. The Journal's web site is located at http://www.elsevier.com/locate/breast | - |
dc.relation.ispartof | The Breast | - |
dc.title | The experience of sentinel lymph node biopsy in Chinese breast cancer patients with prior neo-adjuvant chemotherapy | en_US |
dc.type | Conference_Paper | en_US |
dc.identifier.email | Kwong, A: avakwong@HKUCC.hku.hk | - |
dc.description.nature | link_to_OA_fulltext | - |
dc.identifier.doi | 10.1016/S0960-9776(07)70194-7 | - |
dc.identifier.hkuros | 136505 | - |
dc.identifier.hkuros | 136526 | - |
dc.identifier.volume | 16 | - |
dc.identifier.issue | suppl. 1 | - |
dc.identifier.spage | S51, abstract no. P134 | - |
dc.identifier.epage | S51, abstract no. P134 | - |
dc.identifier.isi | WOS:000257274600164 | - |
dc.publisher.place | United Kingdom | - |
dc.description.other | 10th International Conference on Primary Therapy of Early Breast Cancer, St.Gallen, Switzerland, 14-17 March 2007. In The Breast, 2007, v. 16 n. Suppl 1, p. S51 P134 | - |
dc.identifier.issnl | 0960-9776 | - |